Drug Discovery

Newcells Biotech is the complete supply chain partner for human induced pluripotent stem cell (hiPSC) derived cells and tissues.

We can source tissues from patients, generate hiPSCs from these, and convert the pluripotent cells into the somatic cell types required to model the disease. Our scientists can deliver these in an assay-ready format for discovery programmes.

Successful target identification and validation followed by hit and lead generation are key steps in the identification of clinical candidates. hiPSC based assays are rapidly becoming a key tool to improve discovery productivity.

In vitro cell based disease models using hiPSCs enable new discoveries

Our pedigree of science and technology enables the generation of cells and organoids mimicking for example human retina, skin and the immune system from control and disease cell lines. Our development programmes are focused on optic and lung organoids bringing difficult to obtain tissues to discovery scientists.


Hypoplastic left heart syndrome (HLHS) is a congenital heart disease that affects a number of structures on the left side of a baby’s heart. Without intervention the is prognosis poor, and although drugs and surgical procedures alleviate the symptoms there is currently no cure. The disease is rare with a prevalence of 0.03% in the general population and this has hampered the study of disease pathways. Using iPSC technology, the academic founders of Newcells worked with a team to produce iPSCs from five HLHS patients and health controls that were then differentiated to cardiomyocytes. The HLHS cardiomyocytes exhibited different structural, physiological and significant down-regulation of NOTCH receptors supporting the involvement of this pathway on the pathophysiology of HLHS and the utility of this iPSC approach for modelling disease.


Chronic granulomatous disease (CGD) is a rare genetic immunodeficiency disorder that leads to patients having dysfunctional phagocytic cells such as macrophages. The disease affects around 1 in 200,000 live births and disrupts the ability to create reactive oxygen species that are used by the immune system to kill pathogens such as those that cause pneumonia. Using iPSC technology is was possible to create a cell based model of CGD with monocytes and macrophages that were normal except for their ability to make reactive oxygen species. This model is a valuable addition to the approaches to the study of this life-limiting disease.


Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world and is increasing in prevalence as population age. So called dry AMD is the most common form of the disease, affecting 90% of patients in the last stages of AMD, and currently there are no therapies for this form of the disease. The primary risk factor for the disease is age, with genetic, environmental and lifestyle factors being contributory factors.

There is a critical need for human cell-based models of the disease that mimic its complex pathophysiology.  Newcells Biotech through its work on developing an iPSC based assay for measuring retinal toxicity, has produced retinal organoids from patients with known AMD risk factor mutations such as those affecting Factor H.

Learn about our in vitro cell based disease models

Sign-up to our newsletter for the latest information about our work and projects.